Stephanie A Hagstrom1, Gui-shuang Ying2, Maureen G Maguire2, Daniel F Martin3, Jane Gibson4, Andrew Lotery5, Usha Chakravarthy6. 1. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. Electronic address: hagstrs@ccf.org. 2. Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio; Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. 4. Centre for Biological Sciences, University of Southampton, Southampton, United Kingdom. 5. Faculty of Medicine, University of Southampton, Southampton, United Kingdom. 6. Department of Ophthalmology, Queen's University, Belfast, United Kingdom.
Abstract
PURPOSE: A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an anti-vascular endothelial growth factor (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD). We evaluated whether this association was replicated among patients who participated in the Comparison of AMD Treatments Trials (CATT) or theAlternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial. DESIGN: Cohort studies within randomized clinical trials. PARTICIPANTS: Eight hundred thirty-five patients participating in CATT and 512 patients participating in IVAN. METHODS: Each patient was genotyped for the SNPs rs4576072 and rs6828477 in the VEGFR2 gene. MAIN OUTCOMES MEASURES: Mean change in VA from baseline to 1 year after initiation of treatment with ranibizumab or bevacizumab. Differences in VA response between the patient group homozygous for the minor allele of each SNP and the other genotype groups were evaluated with analysis of variance. Differences in VA response by the number of minor alleles present for either SNP or both combined were evaluated with tests of linear trend. Analyses were conducted separately for CATT and IVAN participants and with both the studies combined. RESULTS: No statistically significant difference in mean change in VA was identified between genotypes of either SNP (P ≥ 0.05). Furthermore, a stepwise analysis failed to show a significant interaction for either SNP based on the number of minor alleles present. The lack of association was similar in both the CATT and IVAN cohorts and whether the analysis combined patients treated with either ranibizumab or bevacizumab or when restricted to patients treated with ranibizumab only. CONCLUSIONS: The CATT and IVAN data do not support a pharmacogenetic association between the 2 VEGFR2 SNPs, rs4576072 and rs6828477, and change in VA in response to anti-VEGF therapy in patients with neovascular AMD.
RCT Entities:
PURPOSE: A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an anti-vascular endothelial growth factor (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD). We evaluated whether this association was replicated among patients who participated in the Comparison of AMD Treatments Trials (CATT) or the Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial. DESIGN: Cohort studies within randomized clinical trials. PARTICIPANTS: Eight hundred thirty-five patients participating in CATT and 512 patients participating in IVAN. METHODS: Each patient was genotyped for the SNPs rs4576072 and rs6828477 in the VEGFR2 gene. MAIN OUTCOMES MEASURES: Mean change in VA from baseline to 1 year after initiation of treatment with ranibizumab or bevacizumab. Differences in VA response between the patient group homozygous for the minor allele of each SNP and the other genotype groups were evaluated with analysis of variance. Differences in VA response by the number of minor alleles present for either SNP or both combined were evaluated with tests of linear trend. Analyses were conducted separately for CATT and IVAN participants and with both the studies combined. RESULTS: No statistically significant difference in mean change in VA was identified between genotypes of either SNP (P ≥ 0.05). Furthermore, a stepwise analysis failed to show a significant interaction for either SNP based on the number of minor alleles present. The lack of association was similar in both the CATT and IVAN cohorts and whether the analysis combined patients treated with either ranibizumab or bevacizumab or when restricted to patients treated with ranibizumab only. CONCLUSIONS: The CATT and IVAN data do not support a pharmacogenetic association between the 2 VEGFR2 SNPs, rs4576072 and rs6828477, and change in VA in response to anti-VEGF therapy in patients with neovascular AMD.
Authors: Philip J Rosenfeld; Howard Shapiro; Lisa Tuomi; Mary Webster; Julee Elledge; Barbara Blodi Journal: Ophthalmology Date: 2011-03 Impact factor: 12.079
Authors: David S Boyer; Andrew N Antoszyk; Carl C Awh; Robert B Bhisitkul; Howard Shapiro; Nisha R Acharya Journal: Ophthalmology Date: 2007-02 Impact factor: 12.079
Authors: Andrew J Lotery; Jane Gibson; Angela J Cree; Susan M Downes; Simon P Harding; Chris A Rogers; Barnaby C Reeves; Sarah Ennis; Usha Chakravarthy Journal: Ophthalmology Date: 2013-09-23 Impact factor: 12.079
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Manuel M Hermann; Freekje van Asten; Philipp S Muether; Dzenita Smailhodzic; Peter Lichtner; Carel B Hoyng; Bernd Kirchhof; Christian Grefkes; Anneke I den Hollander; Sascha Fauser Journal: Ophthalmology Date: 2013-12-21 Impact factor: 12.079
Authors: Gui-shuang Ying; Jiayan Huang; Maureen G Maguire; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Ebenezer Daniel; Michael Klein; Dante Pieramici; John Wells; Daniel F Martin Journal: Ophthalmology Date: 2012-10-06 Impact factor: 12.079
Authors: Stephanie A Hagstrom; Gui-Shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; David G Callanan; Ivana K Kim; Michael L Klein; Maureen G Maguire; Daniel F Martin Journal: Ophthalmology Date: 2013-01-18 Impact factor: 12.079
Authors: S Ennis; J Gibson; H Griffiths; D Bunyan; A J Cree; D Robinson; J Self; A MacLeod; A Lotery Journal: Eye (Lond) Date: 2009-05-01 Impact factor: 3.775
Authors: Peter K Kaiser; David M Brown; Kang Zhang; Henry L Hudson; Frank G Holz; Howard Shapiro; Susan Schneider; Nisha R Acharya Journal: Am J Ophthalmol Date: 2007-10-22 Impact factor: 5.258
Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079
Authors: Laura Lorés-Motta; Moeen Riaz; Michelle Grunin; Jordi Corominas; Freekje van Asten; Marc Pauper; Mathieu Leenders; Andrea J Richardson; Philipp Muether; Angela J Cree; Helen L Griffiths; Connie Pham; Marie-Claude Belanger; Magda A Meester-Smoor; Manir Ali; Iris M Heid; Lars G Fritsche; Usha Chakravarthy; Richard Gale; Martin McKibbin; Chris F Inglehearn; Reinier O Schlingemann; Amer Omar; John Chen; Robert K Koenekoop; Sascha Fauser; Robyn H Guymer; Carel B Hoyng; Eiko K de Jong; Andrew J Lotery; Paul Mitchell; Anneke I den Hollander; Paul N Baird; Itay Chowers Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati Journal: Prog Retin Eye Res Date: 2016-05-06 Impact factor: 21.198
Authors: Moeen Riaz; Laura Lorés-Motta; Andrea J Richardson; Yi Lu; Grant Montgomery; Amer Omar; Robert K Koenekoop; John Chen; Philipp Muether; Lebriz Altay; Tina Schick; Sascha Fauser; Dzenita Smailhodzic; Freekje van Asten; Eiko K de Jong; Carel B Hoyng; Kathryn P Burdon; Stuart MacGregor; Robyn H Guymer; Anneke I den Hollander; Paul N Baird Journal: Sci Rep Date: 2016-11-28 Impact factor: 4.379
Authors: Gui-Shuang Ying; Maureen G Maguire; Wei Pan; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Daniel F Martin Journal: Ophthalmol Retina Date: 2018-06